Ester Fonsatti
Siena, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 19 publications
Novel cellular systems unveil mucosal melanoma initiating cells and a role for PI3K/Akt/mTOR pathway in mucosal melanoma fitness.
Journal: Journal of translational medicine
Published: July 11, 2023
Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome.
Journal: Cancer immunology research
Published: March 07, 2018
"Cancer Bio-Immunotherapy in Siena": Thirteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 8-10, 2015.
Journal: Cancer immunology, immunotherapy : CII
Published: April 20, 2016
ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies.
Journal: Methods in molecular biology (Clifton, N.J.)
Published: April 02, 2016
Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.
Journal: Oncoimmunology
Published: June 01, 2015
Immunologic correlates in the course of treatment with immunomodulating antibodies.
Journal: Seminars in oncology
Published: May 13, 2015
"Cancer Bio-Immunotherapy in Siena": Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014.
Journal: Cancer immunology, immunotherapy : CII
Published: January 21, 2015
Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study.
Journal: The Lancet. Respiratory medicine
Published: January 14, 2015
Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: December 25, 2014
"Cancer Bio-Immunotherapy in Siena": Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013.
Journal: Cancer immunology, immunotherapy : CII
Published: April 08, 2014
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
Journal: The Lancet. Oncology
Published: September 17, 2013
Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma.
Journal: Journal of translational medicine
Published: July 22, 2013
Last Updated: 09/26/2026